Ann: Appendix 4E and 2023 Annual Report, page-16

If I'm reading the thread properly the original question posed by Deckhand was
"My concern is that with these constant delays, that other company are building up their skills in the area of glioblastoma and will surpass patrys and we will be rueing the day." https://hotcopper.com.au/posts/69894944/single

to which Orion asked about the patents https://hotcopper.com.au/posts/69900895/single

Then we get this bit of wisdom from our resident oracle of PAB



which only highlights how mis-informed this poster is despite their long history of promoting/ramping PAB.
To infer that in the area of glioblastoma PAB are ahead of the pack to the clinic is simply wrong!!



and in the area of brain mets imaging agents which PAB has also touted the Deoxymabs as a solution PAB is again well behind


NOT cross promoting just making sure readers are not mislead by optimistic posters drinking their own kool-aide